Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Advanced Hepatocellular Carcinoma
NCT01273662Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Apr 2011
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in hepatocellular carcinoma (HCC), sponsored by National Taiwan University Hospital. Primary endpoint: Disease Stabilization at 8 weeks. Started Apr 2011; status: completed.
02
Drugs
axitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01273662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01273662.